Prophylaxis (HBV)

Clinical Program for H-BIG Formulation for HBV Commence

Published in Hepatitis Weekly, September 9th, 1996

NABI, Boca Raton, Florida, announced the start of an expanded clinical development program for H-BIG (Hepatitis B Immune Globulin [Human] IM 5 percent).

H-BIG is an immunotherapeutic product for the prophylaxis of hepatitis B virus transmission. Under the program, the company has initiated a bioequivalence trial to compare its H-BIG formulation with the currently marketed formulation which has been distributed by NABI since 1992. Preliminary data from a recently-completed study showed sufficient comparability between the two formulations to support initiation of this pivotal bioequivalence trial.

"In line with our strategy of developing NABI's...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1996-09-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry